[1]
M. I. El-ASSAL and D. SAMUEL, “OPTIMIZATION OF RIVASTIGMINE CHITOSAN NANOPARTICLES FOR NEURODEGENERATIVE ALZHEIMER; IN VITRO AND EX VIVO CHARACTERIZATIONS”, Int J Pharm Pharm Sci, vol. 14, no. 1, pp. 17–27, Jan. 2022.